Biblio

Export 66 results:
[ Author(Desc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, et al.. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci U S A [Internet]. 1998;95(2):548 - 53. http://view.ncbi.nlm.nih.gov/pubmed/9435229PDF icon Marc Achen et al., PNAS 1998 (447.59 KB)
Albrecht I, Kopfstein L, Strittmatter K, Schomber T, Falkevall A, Hagberg CE, et al.. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE [Internet]. 2010;5(11):e14109. http://view.ncbi.nlm.nih.gov/pubmed/21124841PDF icon Imke Albrecht et al., PLoS One 2010 (3.37 MB)
Anisimov A, Alitalo A, Korpisalo P, Soronen J, Kaijalainen S, Leppänen V-M, et al.. Activated forms of VEGF-C and VEGF-D provide improved vascular function in skeletal muscle. Circ Res [Internet]. 2009;104(11):1302 - 12. http://view.ncbi.nlm.nih.gov/pubmed/19443835PDF icon Andrey Anisimov et al., Circulation Research 2009 (8.03 MB)PDF icon Andrey Anisimov et al., Circulation Research 2009, supplement (5.9 MB)
Anisimov A, Leppänen V-M, Tvorogov D, Zarkada G, Jeltsch M, Holopainen T, et al.. The basis for the distinct biological activities of vascular endothelial growth factor receptor-1 ligands. Sci Signal. 2013;6(282):ra52. PDF icon Anisimov 2013 Science Signaling (1.92 MB)PDF icon Anisimov 2013 Science Signaling Supplement (2.09 MB)
Anisimov A, Tvorogov D, Alitalo A, Leppänen V-M, An Y, Han EC, et al.. Vascular endothelial growth factor-angiopoietin chimera with improved properties for therapeutic angiogenesis. Circulation. 2013;127(4):424-434. PDF icon Anisimov 2013 (6.56 MB)PDF icon Anisimov 2013 Supplement (4.93 MB)
B
Baluk P, Tammela T, Ator E, Lyubynska N, Achen MG, Hicklin DJ, et al.. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest [Internet]. 2005;115(2):247 - 57. http://view.ncbi.nlm.nih.gov/pubmed/15668734PDF icon Peter Baluk et al., Journal of Clinical Investigation 2005 (1.89 MB)
Batchu KChaithanya, Hänninen S, Jha SKumar, Jeltsch M, Somerharju P. Factors regulating the substrate specificity of cytosolic phospholipase A2-alpha in vitro. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids. 2016;1861(11):1597. PDF icon Batchu et al. - 2016 - Factors regulating the substrate specificity of cy.pdf (986.25 KB)
Batchu KChaithanya, Hokynar K, Jeltsch M, Mattonet K, Somerharju P. Substrate efflux propensity is the key determinant of iPLA-β-mediated glycerophospholipid hydrolysised. Journal of Biological Chemistry [Internet]. 2015;. http://www.jbc.org/content/early/2015/02/23/jbc.M115.642835.abstractPDF icon J. Biol. Chem.-2015-Batchu-jbc.M115.642835.pdf (786.13 KB)
Bry M, Kivelä R, Holopainen T, Anisimov A, Tammela T, Soronen J, et al.. Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation [Internet]. 2010;122(17):1725 - 33. http://view.ncbi.nlm.nih.gov/pubmed/20937974PDF icon Maija Bry et al., Circulation 2010 (2.23 MB)PDF icon Maija Bry et al., Circulation 2010, supplement (17.77 MB)
H
He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, et al.. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res [Internet]. 2005;65(11):4739 - 46. http://view.ncbi.nlm.nih.gov/pubmed/15930292PDF icon Yulong He et al., Cancer Research 2005 (1.82 MB)
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Wedge SR, et al.. Inhibiton of VEGF-C-induced VEGFR-3 activity and lymphatic endothelial cell function by the tyrosine kinase inhibitor AZD2171. In 98th Annual Meeting of the American-Association-for-Cancer-Research [Internet]. Los Angeles, CA: American Association for Cancer Research; 2007. http://dx.doi.org/10.1158/0008-5472.CAN-07-5809PDF icon Heckman et al. - 2007 - Inhibiton of VEGF-C-induced VEGFR-3 activity and l.pdf (236.37 KB)
Heckman CA, Holopainen T, Wirzenius M, Keskitalo S, Jeltsch M, Ylä-Herttuala S, et al.. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res [Internet]. 2008;68(12):4754 - 62. http://view.ncbi.nlm.nih.gov/pubmed/18559522PDF icon Caroline Heckman et al., Cancer Research 2008 (504.8 KB)
Hiltunen MO, Laitinen M, Turunen MP, Jeltsch M, Hartikainen J, Rissanen TT, et al.. Intravascular adenovirus-mediated VEGF-C gene transfer reduces neointima formation in balloon-denuded rabbit aorta. Circulation [Internet]. 2000;102(18):2262 - 8. http://view.ncbi.nlm.nih.gov/pubmed/11056103PDF icon Mikko Hiltunen et al., Circulation 2000 (1.44 MB)
J
Jeltsch M, Jha SKumar, Tvorogov D, Anisimov A, Leppänen V-M, Holopainen T, et al.. CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation. Circulation [Internet]. 2014;129(19). http://circ.ahajournals.org/content/early/2014/02/19/CIRCULATIONAHA.113.002779.abstractPDF icon Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (6.6 MB)PDF icon Postprint of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated VEGF-C activation (Suppl.) (2.38 MB)PDF icon Published version of Jeltsch et al. 2014 (Circulation): CCBE1 enhances lymphangiogenesis via ADAMTS3-mediated... (incl. suppl.) (23.21 MB)
Jeltsch M. VEGFR-3 Ligands and Lymphangiogenesis [Internet]. University of Helsinki. 2002. http://ethesis.helsinki.fi/julkaisut/mat/bioti/vk/jeltschPDF icon Michael Jeltsch, PhD Thesis, 2002 (1.75 MB)
Jeltsch M, Leppänen V-M, Saharinen P, Alitalo K. Receptor Tyrosine Kinase-Mediated Angiogenesis. Cold Spring Harbor Perspectives in Biology [Internet]. 2013;5(9). http://cshperspectives.cshlp.org/content/5/9/a009183PDF icon Jeltsch et al. (2013): Tyrosine Kinase-Mediated Angiogenesis. CSH Persp Biol (934.46 KB)
Jeltsch M. From molecular biology to a causal treatment of lymphatic system disorders [Internet]. 38. Jahreskongress der Deutschen Gesellschaft für Lymphologie e. V. Halle (Saale), Germany: Deutsche Gesellschaft für Lymphologie; 2014. https://jeltsch.org/abstract-Halle2014
Jeltsch M. Functional Analysis of VEGF-B and VEGF-C [Internet]. University of Helsinki. [Helsinki]: Univeristy of Helsinki; 1997. http://urn.fi/URN:NBN:fi-fe977347PDF icon Michael Jeltsch, MSc Thesis, 1997 (3.12 MB)
Jeltsch M, Karpanen T, Strandin T, Aho K, Lankinen H, Alitalo K. Vascular endothelial growth factor (VEGF)/VEGF-C mosaic molecules reveal specificity determinants and feature novel receptor binding patterns. J Biol Chem [Internet]. 2006;281(17):12187 - 95. http://view.ncbi.nlm.nih.gov/pubmed/16505489PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006 (1.04 MB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 1 (1.01 MB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 2 (596.06 KB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 3 (738.98 KB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 4 (710.03 KB)PDF icon Michael Jeltsch et al., The Journal of Biological Chemistry 2006, supplemental data 5 (163.64 KB)
Jeltsch M. Lymphangiogenesis in Health and Disease [Internet]. 41st European Societry of Lymphology (ESL) Congress. Lausanne, Switzerland: European Group of Lymphology; 2015. http://www.eurolymphology.org/JOURNAL/VOL26-N72-2015/#p=10PDF icon Abstract of the Presentation (Michael Jeltsch) (75.34 KB)
Jeltsch M. From Molecular Genetics and Biology to Effective Treatments of Lymphatic Disorders [Internet]. 42nd Congress of the European Society of Lymphology. Mulhouse, France; 2016. http://www.eurolymphology.org/JOURNAL/VOL28-N74-2016/#p=14PDF icon Jeltsch 2016: From Molecular Genetics and Biology to Effective Treatments of Lymphatic Disorders (683.85 KB)

Pages